期刊文献+

术前TPF方案冲击化疗在进展期胃癌的临床跟踪研究 被引量:2

A tracing study on preoperative short course chemotherapy with TPF regimen in advanced gastric cancer
原文传递
导出
摘要 目的研究术前TPF方案短程冲击化疗对进展期胃癌肿瘤细胞凋亡的影响。方法从56例未经治疗的局部进展期胃癌患者中随机抽取36例,以第1天静滴多西紫杉醇(多帕菲)70~75mg/m2、静滴顺铂20mg/d×5d和5-FU0.75/d×5d为主的术前短程冲击化疗;其余20例为空白对照组。观察化疗后原发病灶中肿瘤细胞的凋亡指数和毒副反应。跟踪研究术后3年。结果化疗后所有患者均行根治性手术。术前化疗组肿瘤细胞凋亡指数明显高于对照组[(26.85±12.02)vs.(9.12±7.03)](P<0.01)。毒副反应主要为白细胞减少症(0~I级)、腹泻、恶心呕吐、脱发等,但不影响正常手术。术前化疗组3年生存率明显高于对照组[(72.2%vs.65%)](P<0.05)。结论术前短程冲击化疗能有效促进胃癌细胞调亡,不影响正常手术治疗,能显著延长患者术后生存时间。 Objective To investigate the effects of preoperative short course chemotherapy with TPF regimen on advanced gastric cancer.Methods Of 56 untreated subjects with local advanced gastric cancer,randomly selected 36 cases(group A) received one course of preoperative chemotherapy with intravenous injection of docetaxel 70-75 mg/m2 on the first day,cisplatin 20 mg/d and 5-FU 0.75/d for 5 days.The other 20 cases(group B) were not given preoperative chemotherapy as the controls.The apoptosis index of cancer cells in the primary lesion after chemotherapy and the toxic effects were observed.All cases were followed up for three years after radical surgery.ResultsRadical operations were performed on all 56 patients.The apoptosis index of cancer cells was higher in group A than that in group B /[(26.85±12.02) vs.(9.12±7.03)/](P0.01).Toxic effects of group A were mainly leukopenia(0-Ⅰ),diarrhea,nausea,vomiting and alopecia,which did not affect the surgery.The three-year survival rate was higher in group A than that in group B /[(72.2% vs. 65%)/](P0.05).Conclusion The preoperative short course chemotherapy can effectively enhance apoptosis of cancer cells without influence on the surgery and prolong the three-year survival rate.
出处 《江苏医药》 CAS CSCD 北大核心 2010年第18期2150-2152,共3页 Jiangsu Medical Journal
关键词 胃癌 术前化疗 多西紫杉醇 顺铂 Gastric cancer Preoperative chemotherapy Docepaclitaxel Cisplatin
  • 相关文献

参考文献3

二级参考文献29

  • 1苏华,陈琛,陈秀玲,张江兰,杨燕君,薄爱华,张晓丽,邢立强.凋亡相关基因Bcl-2mRNA在胃癌中的表达[J].江苏医药,2006,32(2):194-194. 被引量:3
  • 2蒲青凡,孙碎康,刘占培,严律南,蔡宇,曹高健,吴文珍,虞希祥.术前胃动脉化疗栓塞对胃癌淋巴结转移灶癌细胞凋亡的影响[J].中国普外基础与临床杂志,2006,13(4):427-430. 被引量:8
  • 3Munoz N,Franceschi S.Epidemiology of gastric cancer and perspectives for prevention.Salud Publica Mex 1997;39:318-330.
  • 4Kamangar F,Dores GM,Anderson WF.Patterns of cancer incidence,mortality,and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world.J Clin Oncol 2006;24:2137-2150.
  • 5Glimelius B,Ekstrom K,Hoffman K,Graf W,Sjodén PO,Haglund U,Svensson C,Enander LK,Linné T,Sellstrom H,Heuman R.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.Ann Oncol 1997;8:163-168.
  • 6Webb A,Cunningham D,Scarffe JH,Harper P,Norman A,Joffe JK,Hughes M,Mansi J,Findlay M,Hill A,Oates J,Nicolson M,Hickish T,O'Brien M,Iveson T,Watson M,Underhill C,Wardley A,Meehan M.Randomized trial comparing epirubicin,cisplatin,and fluorouracil versus fluorouracil,doxorubicin,and methotrexate in advanced esophagogastric cancer.J Clin Oncol 1997;15:261-267.
  • 7Wagner AD,Grothe W,Haerting J,Kleber G,Grothey A,Fleig WE.Chemotherapy in advanced gastric cancer:a systematic review and meta-analysis based on aggregate data.J Clin Oncol 2006;24:2903-2909.
  • 8Van Cutsem E,Moiseyenko VM,Tjulandin S,Majlis A,Constenla M,Boni C,Rodrigues A,Fodor M,Chao Y,Voznyi E,Risse ML,Ajani JA.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:a report of the V325 Study Group.J Clin Oncol 2006;24:4991-4997.
  • 9Cunningham D,Starling N,Rao S,Iveson T,Nicolson M,Coxon F,Middleton G,Daniel F,Oates J,Norman AR.Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med 2008;358:36-46.
  • 10Kang Y,Kang WK,Shin DB,Chen J,Xiong J,Wang J,Lichinitser M,Salas MP,Suarez T,Santamaria J.Randomized phase III trial of capecitabine/cisplatin (XP) vs.continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC):efficacy and safety results.Proceedings of the 42nd Annual Meeting of American Society of Clinical Oncology;2006 June 1-5;Chicago,USA.Alexandria:American Society of Clinical Oncology,2006:18s.

共引文献42

同被引文献15

  • 1孙燕,金懋林,林峰.NCCN胃癌临床实践指南(中国版)[M].北京:2009:MS-8-MS-9.
  • 2Zi‐YuLi,Cherry E.Koh,Zhao‐DeBu,Ai‐WenWu,Lian‐HaiZhang,Xiao‐JiangWu,QiWu,Xiang‐LongZong,HuiRen,LeiTang,Xiao‐PengZhang,Ji‐YouLi,YingHu,LinShen,Jia‐FuJi.Neoadjuvant chemotherapy with FOLFOX: Improved outcomes in Chinese patients with locally advanced gastric cancer[J]. J. Surg. Oncol. . 2012 (8)
  • 3Takafumi Watanabe,Takaki Yoshikawa,Yoichi Kameda,Toru Aoyama,Tsutomu Hayashi,Takashi Ogata,Haruhiko Cho,Akira Tsuburaya,Satoshi Morita,Yumi Miyashita,Junichi Sakamoto.Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case[J]. Surgery Today . 2012 (10)
  • 4Lin BoWang,Rong YueTeng,Zi NongJiang,Wen XianHu,Min JunDong,Xiao MingYuan,Wen JunChen,MeiJin,Jian GuoShen.Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer[J]. J. Surg. Oncol. . 2012 (3)
  • 5Kobayashi Naruyuki,Mizuta Minoru,Otani Hiroki,Kubo Masatoshi,Udaka Tetsunobu,Shirakawa Kazutoyo.[A case of locally advanced gastric cancer responding to pathological CR treated with S-1/CDDP neoadjuvant chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy . 2010
  • 6An JY,Kim HI,Cheong JH,et al.Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy. Yonsei Medical Journal . 2013
  • 7Khoronenko VE,Shemetova MM,Drozhzhina OV,et al.Anaesthesia and intensive care during intraoperative intraperitoneal hyperthermic chemotherapy in patients withgastric cancer literature review and own clinical experience. Anesteziol Reanimatol . 2015
  • 8顾爱琴,张雪艳,包国良,忻宇,宋懿懿,韩宝惠.沙利度胺对肺癌患者血清VEGF、bFGF和TNF-α水平的影响及临床意义[J].中国癌症杂志,2008,18(5):376-379. 被引量:25
  • 9盛贤能,韩晓鹏,李文惠,刘宏斌.进展期胃癌新辅助化疗的现状与进展[J].中国综合临床,2010,26(4):444-446. 被引量:18
  • 10刘超,毛伟征,宋延强,李林浩,林惠忠,李杨.进展期胃癌患者FOLFOX4与XELOX新辅助化疗的临床观察[J].中国现代普通外科进展,2010,13(12):960-963. 被引量:8

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部